Anticoagulation by factor Xa inhibitors (Q34130097)

31 July 2017

title

Anticoagulation by factor Xa inhibitors (English)

1 reference

31 July 2017

1 reference

T Orfeo

1 reference

31 July 2017

S Butenas

1 reference

31 July 2017

K E Brummel-Ziedins

1 reference

31 July 2017

M Gissel

1 reference

31 July 2017

K G Mann

1 reference

31 July 2017

publication date

21 May 2010

1 reference

Journal of Thrombosis and Haemostasis

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

1745-1753

1 reference

The nature of the stable blood clot procoagulant activities

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

The tissue factor requirement in blood coagulation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

The plasma hemostatic proteome: thrombin generation in healthy individuals

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

The challenge of regulating anticoagulant drugs: focus on warfarin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

The origin of the dispute over the discovery of heparin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Low-Molecular-Weight Heparins

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939944

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

28 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03917.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03917.X

Purification of six human vitamin K-dependent proteins in a single chromatographic step using immunoaffinity columns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03917.X

Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03917.X

Oral anticoagulation thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03917.X

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2010.03917.X

Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex

21 January 2018

1 reference

12 December 2020

Platelets and phospholipids in tissue factor-initiated thrombin generation

1 reference

12 December 2020

Thrombin activity of fibrin thrombi and soluble plasmic derivatives

1 reference

12 December 2020

The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model

1 reference

12 December 2020

The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity

1 reference

12 December 2020

Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa

1 reference

12 December 2020

Functional characterization of recombinant human meizothrombin and Meizothrombin(desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition

1 reference

12 December 2020

Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

1 reference

12 December 2020

Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy

1 reference

12 December 2020

10.1111/J.1538-7836.2010.03917.X

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference